Acute erythroid leukemia (AEL) is a high-risk leukemia of poorly understood genetic basis, with controversy regarding diagnosis in the spectrum of myelodysplasia and myeloid leukemia. We compared genomic features of 159 childhood and adult AEL cases with non-AEL myeloid disorders and defined five age-related subgroups with distinct transcriptional profiles: adult, TP53 mutated; NPM1 mutated; KMT2A mutated/rearranged; adult, DDX41 mutated; and pediatric, NUP98 rearranged. Genomic features influenced outcome, with NPM1 mutations and HOXB9 overexpression being associated with a favorable prognosis and TP53, FLT3 or RB1 alterations associated with poor survival. Targetable signaling mutations were present in 45% of cases and included recurrent mutations of ALK and NTRK1, the latter of which drives erythroid leukemogenesis sensitive to TRK inhibition. This genomic landscape of AEL provides the framework for accurate diagnosis and risk stratification of this disease, and the rationale for testing targeted therapies in this high-risk leukemia.
T he past decade has seen major advances in the identification of clinically relevant markers for diagnosis, prognostication and disease monitoring in acute myeloid leukemia (AML) 1, 2 ; however, the genetic bases of several AML subtypes, including AEL, remain poorly characterized [3] [4] [5] . AEL is characterized by proliferation of erythroid and myeloid blast cells in the bone marrow and is associated with a poor prognosis 4, 6, 7 . Since its first description by Di Guglielmo 8 , AEL has been diagnosed and subclassified by morphology alone, using variable criteria of questionable clinical significance without consideration of underlying biological features. In the initial French-American-British (FAB) 9 classification and the subsequent World Health Organization (WHO) 2008 classification
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Articles NATuRE GENETics of myeloid neoplasms, two AEL subtypes were defined based on erythroid percentage and non-erythroid blast proportion 10 . 'M6a' cases had at least 50% erythroid cells and at least 20% blasts of nonerythroid cells in bone marrow. 'M6b' cases were characterized by at least 80% of bone marrow cells' consisting of erythroid precursors without an increase in myeloblasts. Both entities were regarded as subtypes of AML, and consequently, intensive cytarabine-based anti-leukemic treatment regimens were used. However, erythroleukemia classification was significantly changed in the revision of the WHO classification of hematopoietic malignancies 11 . M6a was merged into a hybrid subtype of myelodysplasia and AML (specifically, 'myelodysplastic syndrome (MDS) or AML, not otherwise specified (NOS) (non-erythroid subtype)' based on the percentage of blasts in the bone marrow rather than biological or genetic features. M6b remained as a subtype of ' AML, NOS, acute erythroid leukemia (pure erythroid type)' but with the new criteria of at least 30% proerythroblasts, due to its association with poor prognosis 12 .
There are few data regarding the genomic basis of AEL 13, 14 and none to guide appropriate classification. For example, only three cases with AEL were included in The Cancer Genome Atlas (TCGA) study of AML 1 . As patients with AEL are more likely to receive aggressive induction chemotherapy over the less intensive treatments used for MDS, diagnosis and subclassification have important implications for therapy. In view of these diagnostic uncertainties [13] [14] [15] and the high-risk nature of this leukemia 16 , we performed a comprehensive genomic analysis of both childhood and adult AEL and compared the mutational landscape with that of MDS and non-erythroid AML. Moreover, we examined associations between genomic characteristics and outcome and developed experimental models of AEL to examine leukemogenic potential of genomic alterations and to test the efficacy of targeted therapeutic approaches.
Results
Clinical characteristics. The cohort of 159 cases included 35 pediatric cases (aged 0-20 years, 22%), 8 young adults (aged 21-39 years, 5%), 32 adults (aged 40-59 years, 20%) and 84 older adults (aged ≥60 years, 53%) (Supplementary Tables 1 and 2 and Fig. 1a ). Eight-five percent of cases were centrally confirmed as M6a and 5% were confirmed as M6b according to FAB/WHO 2008 criteria. M6a cases were reclassified under WHO 2016 criteria as MDS (49.1%), AML, NOS (non-erythroid subtype, 13.8%) or AML with myelodysplasia-related changes (AML-MRC, 13.8%). Very poor cytogenetic risk, as defined by the Revised International Prognostic Scoring System (IPSS-R) 17 , was more frequent in patients aged 60 years and older (46.4%) compared with those under age 20 (17.1%; P = 0.0023; Fig. 1b ).
Mutation burden and recurrently mutated genes in AEL.
By means of genome and transcriptome sequencing analysis, we identified a mean of 14.5 non-silent mutations (range 1-39) per case (Supplementary Tables 3-6 and Supplementary Fig. 1a ). The mutational burden was independent of age and WHO 2008 or 2016 subtype, but was higher in cases of very poor cytogenetic risk (18.60 , range 1-33) compared to those of good risk (12.29 , range 1-30, P = 2.81 × 10 ) and intermediate risk (11.65 , range 1-28, P = 0.0001; Supplementary Fig. 1b) . By multimodal analysis of genomic alterations using the Genomic Random Interval (GRIN) 18 model, as well as recurrence and/or known pathogenic role in cancer, we identified 289 altered driver genes, 80 of which retained significance after multiple test correction (Supplementary Table 7 ). Fourteen genes are not included in the Catalogue of Somatic Mutations in Cancer (COSMIC v81; Supplementary Table 7) or described as targets of mutation in AML and MDS 19 . These genes included CCDC30 (n = 4), MAD1L1 (n = 3), UBTF (n = 3) and DDX25 (n = 2). Mutations in FAM186A, MYH4, UBTF or PTPN1 were confirmed to be somatic in nine cases with available germline material. Eleven pathways were recurrently mutated: epigenetic regulation (n = 102, 64.2%), transcriptional regulation (n = 74, 46.5%), cell cycle/tumor suppression, including TP53 mutations (n = 57, 35.9%), DNA methylation (n = 48, 30.2%), splicing/RNA processing (n = 34, 21.4%), Ras signaling (n = 32, 20.1%), non-Ras signaling (n = 48, 30.2%), DNA repair (n = 27, 17.0%), cohesin genes (n = 19, 12.0%), NPM1 (n = 19, 12.0%) and Sonic hedgehog signaling (n = 4, 2.5%) (Supplementary Figs. 1c, 2 and 3, Supplementary Table 8 and Supplementary Note).
The frequency of alteration of these pathways varied according to age at diagnosis and subtype of myeloid malignancy. Genes encoding transcriptional regulators (for example, WT1 and UBTF) were more frequently mutated in children (P = 0.0012) and in AML-MRC (P = 0.0415). Mutations in Ras signaling genes were also most common in patients under 20 years of age (P = 0.0284), whereas older patients were more likely to harbor mutations in DNMT3A, TET2 and ASXL1, genes implicated in clonal hematopoiesis of indeterminate potential (CHIP) [20] [21] [22] . Cohesin genes and NPM1 were most commonly mutated in patients aged 20-59 years than in patients aged less than 20 or over 60 years (P = 0.0150 and 0.0008, respectively) (Fig. 1d) . The majority of sequence mutations in TP53 and genes encoding for epigenetic modifiers (for example, KMT2D, KMT2C, DNMT3A, IDH1/2 and TET2) had clonal mutant allele fractions, consistent with the notion that they are acquired early during tumorigenesis, but because they occurred with other recurrent mutations are insufficient for full leukemic transformation. For example, clonal mutations in splicing factors or cohesin genes were frequently associated with mutations in epigenetic modifiers. Subclonal mutations were most frequently identified in transcription factors and signaling genes, suggesting that these are secondary events (detailed results describing the type and frequency of mutations in pediatric and adult AEL cases are reported in the Supplementary Note and Supplementary Tables 9-11).
TP53 alterations in AEL. Mutations in TP53 genes and tumor suppression genes were present in 57 (35.9%) cases and were more frequent in patients aged 60 years and older (P = 1.60 × 10 Tables 8 and 9 ). All but one of the TP53-mutated cases exhibited alterations of both alleles, as two clonal sequence mutations (28.0% of mutated cases), a mutation and DNA copyneutral loss of heterozygosity (29.0%) or mutation and deletion of the other allele (39%) (Supplementary Fig. 2e ). Sequence mutations were predominantly missense and occurring in the DNA-binding domain ( Supplementary Fig. 2f ), and they were almost exclusively in adult patients, with only two mutated pediatric cases. Notably, in two cases, we identified cryptic complex structural variations (in one case only identifiable by whole-genome sequencing) involving the first intron of TP53 and predicted to prevent translation ( Supplementary Fig. 2g-i) . These cases had the lowest expression of TP53 of all cases ( Supplementary Fig. 2j ). Thus, biallelic alterations of TP53 through sequence or structural alterations are a hallmark of a subset of AEL in adults.
Chromothripsis affects hematopoietic regulators.
A notable finding was the presence of chromothripsis, a massive shattering and reassembly of chromosomes 23, 24 , in 13.1% of AEL cases (18/137 cases with available DNA copy number data (Supplementary Tables  12 and 13 and Supplementary Figs. 4 and 5) . Chromothripsis was more frequent than in MDS (3/301, 1.2%; two-sided P = 1.68 × 10 −7 , Fisher's exact test) 25 and de novo non-erythroid AML (0/197; twosided P = 5.36 × 10 −8 , Fisher's exact test) 1 . It was observed only in adult TP53-mutated cases and was associated with very poor cytogenetic risk (two-sided P = 1.99 × 10 (WHO 2016) . c, Pie charts showing the distribution of the recurrently mutated pathways in the whole AEL cohort. d,e, Pie charts showing the distribution of the recurrently mutated pathways according to age (d) (n = 159 biologically independent samples) and WHO 2016 criteria (e) (n = 149 biologically independent samples). The similarity of somatic alteration prevalence in different leukemia subtypes was evaluated via two-sided chi-square test. Numbers and P values for each pathway and gene are in Supplementary Table 8 . N/A, information not available; AML, NOS, acute myeloid leukemia, not otherwise specified; NES, non-erythroid subtype; ES, erythroid subtype; t-AML, therapy-related AML; t-MDS, therapy-related MDS.
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NATuRE GENETics all cases ( Supplementary Fig. 5 ); this segment harbors the erythroid transcription factor Kruppel-like factor-1 (KLF1) 26 and the hematopoietic regulator nuclear factor I X (NFIX) 27 , suggesting that the chromosomal regions targeted by chromothripsis may have direct roles in leukemic transformation.
Comparative genomic analysis of AEL, AML and MDS. To examine the appropriateness of reclassification of many AEL cases as MDS or non-erythroid AML from the WHO 2008 to 2016 criteria, we compared the genomic features of AEL to independent cohorts of pediatric and adult MDS (Supplementary Table 14) and non-erythroid AML (Supplementary Tables 15 and 16 ). Compared with childhood MDS, childhood AEL was characterized by a higher frequency of mutations in FLT3 and WT1 (20.0% versus 0.96%, P = 0.0003 and 22.86% versus 3.9%, P = 0.002, respectively) and a lower frequency of mutations in GATA2 and ASXL1 (0% versus 14.4%, P = 0.012 and 0% versus 11.5%, P = 0.037, respectively). Compared with non-erythroid childhood AML, childhood AEL showed a higher frequency of mutations in the Ras pathway gene PTPN11 (20% versus 4.7%, respectively, P = 0.005), in epigenetic regulators such as KMT2A (8.6% versus 0.5%, P = 0.012), KMT2D, KMT2C and PHF8 (5.7 % versus 0%, P = 0.023), in the transcriptional regulator UBTF (8.6% versus 0.5%, P = 0.012) and in the RNA-processing gene ELL (5.7 % versus 0%, P = 0.023) (Fig. 2a and Supplementary Table 17 ).
The mutational spectrum of adult AEL was intermediate between those of MDS and AML. For example, we observed much lower frequency of canonical genes mutated in AML, such as FLT3 and NPM1 in AEL, compared with non-erythroid AML (P = 2.13 × 10 and P = 0.004, respectively), but they were more common than in MDS (P = 2.18 × 10 −5 and P = 4.19 × 10
, respectively). Conversely, MDS-associated mutations such as in SF3B1 and ASXL1 were less frequent in AEL compared with MDS (P = 0.018 and P = 0.017, respectively), but more common than in non-erythroid AML (P = 0.034 and P = 0.002, respectively). Moreover, compared to MDS, adult AEL cases had a higher frequency of mutations in the epigenetic regulators ATM (P = 0.023), CREBBP (P = 0.021), ATRX1 (P = 0.006) and SETD2 (P = 0.035), in the Ras signaling gene NF1 (P = 0.007) and in the transcription factors WT1 (P = 0.005) and IKZF1 (P = 0.035). In contrast, infrequently mutated genes in adult with AEL (n = 35 biologically independent samples), MDS (n = 104 biologically independent samples) and non-erythroid AML (n = 192 biologically independent samples). b, Comparison of mutation rates in adult patients with AEL (n = 124 biologically independent samples), MDS (n = 1,410 biologically independent samples) and non-erythroid AML (n = 197 biologically independent samples). Mutated genes are grouped according to their function, and the order within each group is based on the mutation frequency in patients with AEL (from highest to lowest). Only cases for which mutational sequencing data were available for all three cohorts are reported in the figure. Data are from non-silent SNV, indel or internal tandem duplication (ITD) sequence mutations. Frequency of mutations in the different leukemia subtypes were compared using two-sided Fisher's exact tests (numbers for each group and P values for each gene are in Supplementary Tables 17 and 18) . P values are from Fisher's exact test. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001. P values in yellow are from AEL versus MDS; those in blue are from AEL versus non-erythroid AML (NE-AML). Genes whose mutation frequency is statistically different among the different myeloid entities are in bold, and their colors depend on the subtype with the higher frequency (purple, AEL; yellow, MDS; blue, NE-AML). Genomic subgroup
Gene expression subgroup The primary assignment bootstrap probability was greater than 50% in 128 of 130 subjects; the mean primary assignment bootstrap probability across all subjects was 82.6%.
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AEL were PPM1D (P = 0.008) and SRSF2 (P = 0.006). Interestingly, disease-associated Ras mutations were identified, with NRAS rarely mutated in AEL compared to non-erythroid AML (0.8% versus 7.6%, P = 0.007) and NF1 with an opposite trend (5.7% versus 1.0%, P = 0.030) (Fig. 2b , Supplementary Note and Supplementary Tables  18 and 19) . TP53 mutations are a hallmark of AEL, and they were present in 37.9% of adult cases (39.5% of all adult AEL cases if cases with structural variations of TP53 were also included) but were less common in MDS (19.9%, P = 1.02 × 10
) and non-erythroid AML (6.6 %, P = 4.15 × 10
−12
). Thus, mutational prevalence varies significantly between the three major subtypes of myeloid neoplasms (AEL, non-erythroid AML and MDS) in both children and adults, suggesting that the recent reclassification of many AEL cases as MDS or AML is unfounded from a mutational perspective.
Gene fusions targeting erythroid development and signaling.
Chromosomal rearrangements resulting in expression of an inframe fusion of two genes were found in 26.0% of AEL cases and were more frequent in cases with very poor cytogenetic risk. The only recurrent fusions were those involving NUP98 in pediatric cases (20.0% of all pediatric cases). ZMYND8-RELA, identified in a single case, has been previously reported 28 , indicating that it is also recurrent in pediatric AEL. Additional gene fusions involved the erythroid transcription factor GATA1 (MYB-GATA1) 29 or most commonly affected epigenetic regulators (KMT2A rearrangements, Table 5 , Fig. 3a and Supplementary Fig. 7 ).
ZEB1-KDM4C and SMARCA4-CBS) or signaling pathways (APLP2-EPOR, DEK-NUP214, ASNS-PTPN1, SRC-VWC2, RUNX2-STAT3 and PRKAR2B-PIK3C) (Supplementary
AEL comprises distinct genomic and gene expression groups.
Both genomic alterations and gene expression profiles classified AEL cases into prognostically significant groups, independent of WHO subtype and with close but incomplete overlap in membership between the groups in each classifier. We defined five distinct genomic subtypes based on patterns of mutation association and exclusivity (Fig. 3c , Supplementary Table 20 and Supplementary Fig. 8 ): mostly adult, TP53 deregulated (n = 51, 32%); NPM1 mutated (n = 19, 12%); KMT2A mutated/rearranged (n = 18, 11%); pediatric, NUP98 rearranged (n = 7, 4%); and adult, DDX41 mutated (n = 5, 3%). 37% of cases lacked an identifiable exclusive recurrent founding genetic alteration, but as a group exhibited a higher frequency of mutations in ASXL1 (16.6% versus 5.1%, P = 0.02), and in the splicing factor gene SF3B1 (8.3% versus 1.0%, P = 0.03) compared to the other groups. Mutation patterns were subtype dependent, with mutations in tumor suppression genes more frequent in NUP98-fusion-positve AEL and TP53-mutated AEL (P = 3.84 × 10
) and mutation in cohesin genes more frequent in NPM1 and KMT2A-mutated/rearranged subgroups (P = 7.39 × 10
−5
). Mutations in genes with a role in DNA methylation never co-occurred with NUP98 fusions or DDX41 mutations (P = 0.028) (Supplementary Table 21 ).
Genomic subtype-defining lesions were grouped by gene expression analysis in four distinct AEL subgroups (Fig. 3d) . Group 1 was characterized by mutations in TP53 (54.9%) and overexpression of LTF, DLK1 and MECOM. Group 2 and group 3 were characterized by mutations in NPM1 (56.0%) and KMT2A (68.8%), respectively, and by overexpression of PRDM16 and HOX genes (HOXB5, HOXB6, HOXB8 and HOXB9). Group 4 included cases with NUP98 fusions (25%) or additional cases with TP53 mutations (33.3%) and was characterized by overexpression of TMEM246, PLOD2, FREM1, MECOM and low expression of DEFA1B and DEF4A, compared to the other groups (Supplementary Table 22 and Supplementary Data).
Genomic determinants of outcome. AEL is often associated with poor prognosis 7 ; however, except for cytogenetic risk factors, the biological reasons for this have been unclear. Age, IPSS-R cytogenetic risk groups, therapy-related leukemia, genomic subgroups, gene expression classes, genetic pathways (tumor suppression) and individual genetic lesions (TP53, NPM1, FLT3, RB1) were associated with outcome in univariate analysis (Fig. 4 , Supplementary  Tables 24 and 25 and Supplementary Fig. 9 ). Among the genomic subgroups, TP53 mutations were associated with very poor prognosis (median survival of 13 months, with no patients surviving at 5 years), whereas individuals with NPM1 mutations had excellent outcomes, with a 5-year survival of 87.5% (95% confidence interval (CI), 60.5-100). Subgroups defined by gene expression also had marked variation in outcome, with group 4 (NUP98 rearranged or a subset of TP53-mutated cases) having the worst outcome, with an estimated 5-year survival of 9.1% (0.0-21.1). Conversely, group 2 (NPM1 mutated, HOXB9 overexpressing) showed a better outcome, with a 5-year survival of 81.6% (55.7-100). These associations were also observed in a subset of patients treated most intensively, with chemotherapy-based regimens (n = 81), with IPSS-R cytogenetic risk groups, genomic and gene expression subgroups, genetic pathways (tumor suppression) and individual genetic lesions (TP53 and NPM1) being associated with outcome in univariate analysis (Supplementary Table 26 ). Chromothripsis or mutation burden (as measured by number of mutated driver genes per individual patients) was not independently associated with outcome in this cohort (Supplementary Table 25 and Supplementary Fig. 9 ). In a multivariate analysis incorporating genetic, clinical and diagnostic variables, the gene expression classes but not the WHO subgroups were the most powerful predictors of outcome (Supplementary Table 25 ).
Functional modeling of gene fusions. NUP98-KDM5A, as previously described 30 
, but not other fusions (MYB-GATA1, ASNS-PTPN1, PFN1-SCHIP1, CDC37-IL27RA, NPM1-MLF1
or RUNX2-STAT3) was sufficient to confer self-renewal in vitro ( Supplementary Fig. 10 ) and promoted the development of a serially transplantable myeloid (MPO-and B220-positive) leukemia in mice. These results support our genomic observations that NUP98-KDM5A-positive cases, in contrast with cases with non-NUP98 fusions, harbor few additional mutations, and this lesion is probably sufficient for leukemogenesis (Supplementary Note, Supplementary  Tables 29 and 30 and Supplementary Fig. 10 ). In contrast, the other fusions were observed together with alterations in other recurrently mutated genes, suggesting cooperativity between these events. Although NUP98-KDM5A fusion was recurrent in AEL, the leukemia established in mice was myeloid, suggesting that additional alterations (for example, RB1 deletions) or a different cell of origin are responsible for the leukemia phenotype.
Targetable signaling mutations in AEL.
A mutation in at least one signaling pathway amenable to inhibition by tyrosine kinase/JAK2/ Ras inhibitors was identified in 44.7% of cases ( Supplementary  Fig. 3a,b) Fig. 3c ). In these cases, the mutations had lower variant allele frequencies than in cases with only one mutation, indicating presence in subclones ( Supplementary Fig. 3d ). Mutations in the JAK-STAT pathway genes (FLT3, JAK2, EPOR and SH2B3) occurred in 12.6% of all cases, and they co-occurred with TP53 mutations in 20% (4/20) of cases.
Additional mutations affected the phosphatidylinositol 3-kinase (PI3K)-AKT signaling pathway (7.5%) and a variety of different kinases (for example, ALK, NTRK1, ABL class genes and PDGFRB) in 15.7% of all cases (Supplementary Fig. 3 ). NTRK1 mutations Articles NATuRE GENETics were observed in three cases, and although expressed, were not associated with higher NTRK1 expression compared with cases with wild-type NTRK1 (Supplementary Fig. 11a ), supporting the notion that NTRK1 is expressed in erythroid lineages, as previously shown 31, 32 . NTRK1 fusions or mutant alleles have been described to occur and play a role in solid tumors and hematological malignan- At-risk numbers for each analysis are provided in the figures. Outcome associations were analyzed with the log-rank test. AML, NOS acute myeloid leukemia, not otherwise specified; NES, non-erythroid subtype; ES, erythroid subtype; t-AML, therapy-related AML; t-MDS, therapy-related MDS.
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NATuRE GENETics cies [33] [34] [35] [36] , but they have not been reported in AEL, so we sought to examine their role in leukemogenesis and targetability. The mutations affected three residues in the tyrosine kinase domain (H498R, G617D and H766R) that are not involved in the binding of TRK inhibitors such as entrectinib (Fig. 5a,b) and do not alter cellular localization (Supplementary Fig. 11b ). In focus formation assays, ). The structure is represented similar to that in ref.
44
, with the Asp-Phe-Gly (DFG) motif in orange, the activation segment in magenta, the kinase insert domain in green, the hinge in cyan, and the G loop in pink. 
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NATuRE GENETics all three NTRK1 mutants promoted morphological transformation and loss of contact inhibition of NIH/3T3 cells (Fig. 5c) , which was abrogated by entrectinib ( Supplementary Fig. 11c,d) .
To examine leukemogenic potential of NTRK1 mutations, wildtype or mutated NTRK1 were expressed in lineage-negative hematopoietic stem and progenitor cells (Lin -HSPCs) from wild-type or TP53
R172H (equivalent to human TP53 R175H , present in two NTRK1-mutant cases) C57BL/6 mice 37 . Whereas the expression of TP53
R172H alone resulted in disseminated T-cell lymphoma, NTRK1
H498R/G617D/H766R or wild-type NTRK1, together with TP53 R172H , promoted the development of an aggressive and transplantable erythroid leukemia, with significantly shorter latency observed in mice inoculated with Lin -HSPCs harboring NTRK1/TP53 co-mutant compared to TP53-mutant, NTRK1 wild-type HSPCs (Fig. 5d-g and Supplementary Fig. 11 ). To further investigate the mechanisms of leukemogenesis in the NTRK1/TP53 models of leukemia, we examined leukemic gene expression profiles by RNA-seq (Supplementary Tables 31 and 32 ) and mutational burdens by whole-exome sequencing (Supplementary Table 33) in both primary and secondary recipient mice (total = 16 samples for RNA-sequencing and 16 samples for exome sequencing) and in untransduced Lin -HSPCs. NTRK1/TP53 co-mutant tumors had a distinct gene expression profile characterized by upregulation of genes overlapping significantly with CBFA2T3 target genes ( Supplementary Fig. 11f and Supplementary Tables 31 and 32) . However, these results may have been due to a relative frequency of HSPCs within the heterogeneous populations that were compared and not linked to the molecular mechanism of transformation by NTRK1/TP53. Compared to NTRK1 wild-type/TP53-mutant tumors, the genes perturbed by NTRK1/TP53 co-afterations overlapped significantly with KLF1, EWSR1-FLI 38 and TP53 target genes and showed enrichment of genes upregulated in HSPCs from adult bone marrow and fetal liver (Supplementary Tables 32). NTRK1/TP53 co-mutant tumors harbored few additional somatic alterations (n = 8 in NTRK1 Table 33 ). These findings and the significantly shorter latency of NTRK1-mutant tumors indicates NTRK1 is an oncogenic driver, but additional mutations are required to drive leukemogenesis in cells expressing wild-type NTRK1. Both tumors from wild-type NTRK1/mutant TP53 and NTRK1/TP53 co-mutant mice were characterized by the development of multiple chromosomal aneuploidies ( Supplementary Fig. 11i) , with recurrent amplifications of chromosomes 3, 8, 11 and 15 ( Supplementary Fig. 11j ).
NTRK1/TP53 co-mutant tumors were highly sensitive in vivo to larotrectinib, an oral, potent and selective inhibitor of TRK 39, 40 . Leukemia remained undetectable for at least 3 months after cessation of treatment ( Fig. 5h and Supplementary Fig. 11k ).
Discussion
Here, we describe the genomic landscape of childhood and adult acute erythroid leukemia, which has been subjected to variable classification schema and was excluded from the erythroid/myeloid category of ' AML, NOS' in the revised WHO 2016 classification 11 . This reclassification has resulted in great uncertainty regarding diagnosis, risk classification and assignment of therapy of appropriate intensity 13, 14 . We show that although many of the most common targets of mutation in AEL are observed in MDS and AML, the frequency and constellations of lesions are distinct in both childhood and adult AEL. Moreover, mutational spectra are highly age dependent, with mutations of genes driving clonal hematopoiesis (for example, DNMT3A, TET2, ASXL1 and TP53) more commonly observed in older adults compared to children. This suggests that in adults, AEL may arise from acquisition of mutations on the background of clonal hematopoiesis. In contrast, in children, we observed recurrent NUP98 fusions, which harbored few additional alterations, suggesting that this lesion is sufficient for leukemogenesis.
In this study, we have shown that AEL comprises multiple molecular subgroups in both children and adults. The mutational spectrum is intermediate between MDS and AML: mutations common in non-erythroid AML are less frequent in AEL, but they are more common than in MDS. Conversely, MDS-associated mutations are less frequent in AEL, but more common than in non-erythroid AML.
Genomic alterations and gene expression profiles closely correlated and classified cases. Moreover, they were the strongest predictors of outcome, suggesting that they should be incorporated in a revision of the diagnostic and prognostic criteria. Low HOXB9 expression, TP53 mutations, RB1 copy number loss and FLT3 mutations were associated with poor outcome, whereas NPM1 expression conferred good prognosis.
The importance of comprehensive genomic analysis incorporating detection of structural variants and gene expression is highlighted by the heterogeneity and complexity of the genomic alterations identified in this study, such as chromothripsis and cryptic TP53 structural variations, suggesting that targeted sequencing approaches will underestimate and potentially misclassify leukemia cases. Here we showed that not only the multiple types of alteration but also the uniform biallelic alteration of TP53 that has not been characterized in prior reports are a features of adult AEL and key drivers of AEL leukemogenesis as supported by the potent interaction with NTRK1 in our in vivo mouse model. AML therapy has not changed considerably in over 30 years and is poorly tolerated by older patients, who compose the majority of cases. However, in recent years, considerable progress has been made in understanding disease pathogenesis in AML, with the identification of multiple somatically acquired driver mutations that affect prognosis and suggest targets for novel therapies. Clinical trials based on genetics are commonly utilized and provide prognostic and clinical management regardless of WHO classification or morphologic subtype of leukemia for most of the AML patients with recurrent genetic alterations (for example, FLT3 mutations) 41 . However, except for few cases, AEL was often underrepresented in the genomic screening studies of AML and/or MDS, and clear guidelines on how to treat these patients are lacking. Thus, the identification and validation of specific biomarkers as provided in this study will guide future studies that tailor therapy in specific subtypes. We developed a highly penetrant erythroid leukemia mouse model of NTRK1 and TP53 mutations, which was exquisitely sensitive in vivo to inhibition with larotrectinib, an orally administered, potent and selective inhibitor of NTRK. The efficacy of selective NTRK inhibitors on NTRK-driven AML and ALL was also recently reported 34, 36 . Taken together, these data demonstrate the sensitivity of NTRK1-mutated patient leukemic cells to NTRK inhibitors and enhance the relevance of these inhibitors for future clinical trials.
Moreover, because TP53 mutations and/or adverse cytogenetics were recently found to have very high response rates to hypomethylating agents (HMA) in AML 42 and AEL 7 , HMA could represent a new therapeutic approach to improve outcome for this disease where TP53 mutations represent the most common initiating event for AEL.
While our data show that each erythroleukemia consists of multiple subgroups with distinct constellations of genomic alterations, they do not directly address the relative importance of genomic alteration versus the hematopoietic (or erythroid) progenitor in which the lesions are acquired as determinants of erythroid lineage. As many recurrently mutated genes are also observed in other myeloid leukemias, cell of origin is likely important; however, the Articles NATuRE GENETics remarkably aggressive leukemia induced by concomitant NTRK1 and TP53 alterations indicates that mutation co-occurrence is an important determinant of disease lineage.
These data indicate that genomic analysis provides a more accurate foundation for the diagnosis and therapy of AEL by identifying different recurrent genetic alterations in subgroups with different clinical outcomes and potential targets for novel therapies. Toward this direction, our study provides insights into genetic alterations that predominate in AEL compared to AML and MDS and define distinct subtypes with different genomic background and therapeutic targeting. 
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Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41588-019-0375-1. 17 . The full patient characteristics are described in Supplementary Tables 1  and 2 and Fig. 1a,b . Patients with confirmed AEL were divided into the following four age groups: pediatric cases (n = 35; age 0 to 20 years), young adults (n = 8; age 21 to 39 years), adults (n = 32; age 40 to 59 years) and older adults (n = 84; age ≥60 years). Patients were from the MLL Munich Leukemia Laboratory, Germany (n = 100); the Children's Oncology Group (COG; see URLs) (n = 12); the Centre for Cancer Biology, University of South Australia, Australia and SA Pathology (n = 10); the Australian Leukaemia and Lymphoma Group (ALLG) Tissue Bank (n = 9); the Japanese Paediatric Leukaemia/Lymphoma Study Group (JPLSG), Japan (n = 9); St. Jude Children's Research Hospital, USA (n = 7); the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP), Italy (n = 4); the Australian Centre for Blood Diseases, Alfred Hospital and Monash University, Australia (n = 4); and the University of California at San Francisco, CA, USA (n = 1). Patients were enrolled onto clinical trial protocols of the following groups or centers: AML 2002/01 protocol from the AIEOP 45 , JPLSG AML-05 trial 46 , German-Austrian AML Study Group (AMLSG) 07-04 study (ClinicalTrials.gov identifier: NCT00151242) 47 
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Children's Cancer Group (CCG) -2961 study (NCT00002798) 48 , European LeukemiaNet (ELN) 49 and/or institutional protocols. AEL samples from COG were from patients treated on recent COG AML trials who achieved an initial remission to induction chemotherapy. These trials randomized type or timing of induction therapy (CCG-2961) and the addition of gemtuzumab ozogamicin to backbone therapy in a single-arm pilot (AAML03P1) or randomized fashion (AAML0531) 50 . All patients or their legal guardians gave written informed consent for sample collection and research. The study was approved by the St. Jude Children's Research Hospital Institutional Review Board.
Non-erythroid AML. Pediatric and adult samples with non-erythroid AML were from Therapeutically Applicable Research to Generate Effective Treatments (TARGET) (n = 192) and from The Cancer Genome Atlas (TCGA) study (n = 197), respectively 51 . TARGET samples were from COG AML trials, as described above, and publicly available data can be found at The National Cancer Institute Portal (see URLs) and in reference 52 . TCGA patient characteristics were described in detail in ref. 51 , and publicly available data can be found at the Genomic Data Commons Data Portal (see URLs).
Myelodysplastic syndrome. 1,514 cases (n = 104, age 0 to 20 years; n = 1,410, age ≥21 years) with myelodysplastic syndrome (MDS) were from the Center for International Blood and Marrow Transplant Research (CIBMTR) repository, and their characteristics have been reported in Lindsley et al. 53 . Patients were not included if the percentage of blasts in the bone marrow or blood was 20% or more or if they had received a diagnosis of chronic myelomonocytic leukemia or overlap myelodysplastic-myeloproliferative neoplasms.
Cell lines. TF-1 (ref. 54 ) and HEL 92.1.7 (ref. 55 ) (hereafter referred to as HEL) cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were thawed and cultured according to ATCC instructions. Immunophenotypic and cytogenetic analyses were performed prior to DNA and RNA extraction.
Genomic studies. Genomic profiling of patient samples and the TF-1 and HEL cell lines was performed by whole-genome (n = 6), exome (n = 142 patients and two cell lines), transcriptome (n = 139 tumor patients and two cell lines) or targeted sequencing (n = 12 patients) and SNP microarray genotyping to identify DNA copy number alterations (n = 137 patients and two cell lines) (Supplementary Table 1 ).
Whole-genome sequencing. Five pediatric cases (paired tumor-germline samples) and one older adult (unpaired tumor sample) had whole-genome sequencing (WGS) (Supplementary Table 1 ). Sequencing libraries were constructed for WGS cases from genomic DNA and sequenced using combinatorial probe anchor ligation by Complete Genomics Inc. (CGI) 56 . Reads were mapped to the GRCh37 reference human genome assembly by the CGI Cancer Sequencing service using software version 2.1 of the CGI cancer analysis pipeline (see URLs). Methods and publicly available data are provided in details at the Therapeutically Applicable Research to Generate Effective Treatment (TARGET) data portal (see URLs).
Whole-exome sequencing. Whole-exome sequencing was performed in 122 unpaired and 20 paired tumor-germline samples with AEL (Supplementary Table  1 ). Germline samples were from flow cytometry-sorted CD45 high /CD3
+ cells (n = 2), mesenchymal cells (n = 7) and remission (n = 15); four cases had wholeexome sequencing of both remission samples and mesenchymal cells. DNA was extracted using the AllPrep DNA/RNA Mini Kit (Qiagen). Library construction utilized DNA tagmentation (fragmentation and adapter attachment) performed using the reagent provided in the Illumina Nextera rapid exome kit and was performed using the Caliper Biosciences Sciclone G3 (PerkinElmer). First-round PCR (ten cycles) was performed using Illumina Nextera kit reagents and clean-up steps using AMPure XP beads (Beckman Coulter Genomics/Agencourt). Target capture utilized Illumina Nextera Rapid Capture Expanded Exome and supplied hybridization and associated reagents. The pre-hybridization pool size was 12 samples, and second-round PCR (ten cycles) was performed with Nextera kit reagents. Library quality control and sequencing was performed as previously described 57 .
Whole-exome sequencing analysis. Whole-exome sequencing mapping, coverage and quality assessment, single-nucleotide variation (SNV) and insertion/deletion (indel) detection and annotation for mutations have been described previously 58 . The reference human genome assembly NCBI Build 37 was used to map all samples. The mapping statistics and coverage for each sample are summarized in Supplementary Table 34 .
More specifically, putative SNVs and indel variants were detected using SNPdetector 59 . Further evaluation of SNVs and indels was performed by manual review of the BAM files using Bambino 60 . Non-silent coding variations present in tumors, but absent in normal tissue, were considered somatic mutations. To remove additional germline variations from the dataset generated by sequencing tumors without matching germline samples, new non-silent mutations were compared to the Exome Variant Server (EVS) (National Heart, Lung, and Blood Institute Exome Sequencing Project; see URLs) and to a database of germline variations identified in the Pediatric Cancer Genome Project 61 . Novel variants that passed this germline filter were annotated with dbSNP v141 and manually reviewed. Those at a site of known somatic sequence mutations in the Catalogue of Somatic Mutations in Cancer (COSMIC) database (see URLs) 19 or at a gene included in COSMIC cancer gene census were grouped as putative somatic mutations, and others were considered variants of unknown origin. The analysis pipeline is shown in Supplementary Fig. 12a,b. RNA-sequencing. RNA was extracted with an AllPrep DNA/RNA Mini Kit (Qiagen). Transcriptome sequencing (RNA-sequencing) was performed using the TruSeq library preparation on the Illumina HiSeq 2000 platform as previously described 62 . Briefly, all sequencing was paired end and performed using total RNA and stranded RNA-sequencing (n = 104), polyadenylated-selected nonstranded sequencing (n = 31) or both (n = 6 including the two AEL cell lines) (Supplementary Table 1) .
RNA-sequencing analysis. Paired-end reads from RNA-seq were aligned using STAR 63, 64 to the following four databases: (i) human NCBI Build 37 reference sequence, (ii) RefSeq, (iii) a sequence file that represents all possible combinations of non-sequential pairs in RefSeq exons, and (iv) AceView flat file (University of California Santa Cruz, UCSC), representing transcripts constructed from human expressed sequence tags (ESTs). The mapping results were aligned to human reference genome coordinates, and final BAM files were constructed by selecting the best alignment, as previously described 35 . The mapping statistics and coverage for each RNA-seq sample are summarized in Supplementary Table 35 . Structural variation detection in RNA-seq was carried out using CICERO, an algorithm that uses de novo assembly to identify structural variations in RNA-seq data 35 . Gene expression was quantitated using HTSeq and normalized using Trimmed Mean of M values (TMM) method in edgeR 65 . In order to simultaneously analyze poly(A)-enriched and total stranded RNA-seq samples, we utilized six cases that have been sequenced by both protocols to calculate an averaged scale factor for each gene, and used this scale factor to correct all poly(A)-enriched samples to remove platform specific bias. For samples without WES but with RNA-seq available, we double checked all the cancer gene SNVs identified from WES in this cohort, to see if there is evidence in these RNA-seq-only samples. The analysis pipeline is shown in Supplementary Fig. 12c . Statistical testing of differences in gene expression between subgroups were performed using limma 66 .
Bootstrap evaluation of hierarchical clustering. A rigorous bootstrap procedure was applied to the RNA-seq data (n = 139) to define gene expression subgroups in an unsupervised manner. 130 cases were evaluable for this analysis (Supplementary Table 1 ). In order to avoid variations due to technical artifacts, nine samples (SJAEL018159 to SJAEL018168, Supplementary Table 1) were excluded, because the sequencing data were not generated at St. Jude Children's Research Hospital.
The bootstrap procedure developed by Pawlikowska et al. 67 was used to quantify the reproducibility of 504 hierarchical cluster analysis methods defined by all 504 combinations of 28 considered values for the number of selected genes (m = 1, 2, 3,…, 10, 20, 30,…,100, 200, 300, …, 1,000 genes), nine considered values for the number of subgroups to be defined (k = 2, 3,…,10), and two considered dendrogram linkage methods (complete or average). Each cluster analysis method was applied to the observed RNA-seq data (log 2 counts per million, CPM, mapped reads) and each of 500 bootstrap datasets obtained by resampling subjects with replacement. The reproducibility of each cluster analysis method was computed by summarizing the consistency of its subgroup assignments across the 500 bootstrap datasets.
We then selected specific cluster analysis results for further analysis. Among each set of cluster analysis methods that sought to identify a given number of clusters k, we selected the method that, with the best bootstrap reproducibility among those that discovered k subgroups, assigned at least ten subjects to each discovered subgroup, and used at least 2 k features. On the basis of these criteria, we selected one set of results yielding two subgroups, one set of results yielding three subgroups, and one set of results yielding four subgroups for further consideration.
In this study, we then used the total covariance about the densest interval (total CADI) metric to select features for subgroup discovery analysis. For one pair of genes, the CADI is computed as where x i and y i represent gene expression values of two genes for individual i, and x* and y* are robust center estimates defined as the mean of observations in the narrowest interval containing at least half the data values (the densest interval) 68 . For each gene, its CADI with every other gene was computed using the formula above, and its total CADI was computed as the sum of its CADI with all other genes.
Targeted next-generation sequencing. Seven AEL cases from COG AML0531 (Supplementary Table 1) were analyzed by targeted next-generation sequencing (NGS) of 400 candidate genes. The procedure has been described in detail in an independent manuscript 52 . One sample (SJAEL047111) was analyzed using an integrated DNA/RNA target capture NGS assay, which is able to detect different classes of genomic events, including base substitutions, indels, copy number aberrations (CNAs), and chromosomal rearrangements, as previously described 69 .
Sequencing validation. For validation of SNV, indels or internal duplications, we performed a comparison between the data generated at St. Jude Children's Research Hospital (Memphis, USA) by whole-exome and RNA-seq with those previously generated from the same samples but from independent DNA/RNA extractions at MLL Munich Leukemia Laboratory (Munich, Germany) by means of Sanger or targeted sequencing approaches. Sequence variations were analyzed using Sanger sequencing with BigDye Term v1.1 cycle sequencing chemistry (Applied Biosystems) or by the 454 GS platform (454 Life Sciences) 70 , or were studied using a combination of a microdroplet-based assays (RainDance, Billerica, MA) and the MiSeq sequencing instrument (Illumina, San Diego, CA) 71 . The partial tandem duplication (PTD) in the KMT2A gene was confirmed by quantitative PCR 72 , the internal tandem duplication (ITD) in the FLT3 gene was analyzed by fragment length analysis 73 (Supplementary Table 39 ). For validation of gene fusions, primers were designed upstream and downstream of each fusion's breakpoint and used for reverse transcription and PCR using Phusion enzyme (New England Biosciences) from patient samples (Supplementary Table 36 ). The PCR products were purified using the Wizard SV Gel and PCR Clean-up system (Preprotech), and sequences were verified via Sanger sequencing. The sequenced amplicon was aligned to a reference fusion sequence generated from National Center for Biotechnology Information (NCBI) using the contigs obtained from RNA-seq. The results were analyzed using CLC Main Workbench (Qiagen).
Single-nucleotide polymorphism microarrays. Samples (n = 122 unpaired and n = 15 paired tumor-germline samples) were genotyped using Affymetrix SNP 6.0 microarrays according to the manufacturer's instructions. CEL files were generated using GeneChip Command Console Software. SNP calls were generated using Genotyping Console (Affymetrix) and the Birdseed v2 algorithm with default parameters. Array normalization and copy number inference were performed according to a previously published workflow 74 . Normalized data were viewed in dChip 75 , and regions with abnormal copy number were identified computationally by circular binary segmentation (CBS) 76 and analyzed as previously described 74 . Evidence of chromothripsis was defined as the presence of at least ten changes in segmental copy number between two or three copy number states on an individual chromosome 24 . Inferred copy number log 2 data from chromosomes with chromothripsis were exported from dChip and visualized in USCS Genome Browser.
Fluorescence in situ hybridization. Cell pellets from various primary leukemia samples that had been fixed in Carnoy's fixative were used for FISH analysis. Probes were prepared from appropriate BAC clones or contigs of fosmid clones. Purified DNAs were labeled by nick translation with either Alexa Fluor 488 dUTP or Alexa Fluor 594 dUTP. All hybridizations were performed as two-step threeprobe experiments. The first hybridization consisted of 5′ and 3′ probes from the target gene to show disruption due to chromosomal rearrangement. Images were made from this first hybridization, and microscope coordinates were recorded. Cases with a positive result on the first hybridization were subjected to a second hybridization using a probe for the suspected fusion partner. The same cells that had been imaged after the first hybridization were imaged again after the second hybridization. This second experiment confirmed that when a gene disruption is found in the first hybridization, it either is or is not accompanied by fusion in the second hybridization. This type of approach can distinguish between gene fusion events and gene disruption events not accompanied by fusion.
Genomic Random Interval (GRIN) model. GRIN was used to perform an integrative analysis of multimodality genomic data (DNA copy number alterations, mutations, structural rearrangements and expression levels from RNA-seq) to systematically identify genes in which perturbation of more than one genomic modality is likely to signify a role as a putative tumor suppressor. GRIN computes a P value for the number of subjects with a copy number gain, copy number loss, sequence mutation or structural rearrangement, as previously described 18, 57 .
To evaluate the association of each type of lesion with expression for each gene, the Wilcoxon rank-sum test 77 was used to compare the RNA-seq log 2 -counts per million reads (CPM) expression values of subjects with the specific type of lesion (mutation, fusion, copy number gain, copy number loss) with those of subjects with no detected lesion. For each type of lesion, the q value 78 with the P-value moment-based estimator 78 was used to characterize the false discovery rate of performing multiple tests across many genes.
Identification of potential oncogenic driver genes. To identify potential driver genes, the list of mutated genes obtained from sequencing and SNP array analyses was compared with the cancer gene census from the COSMIC database 19 (see URLs) according to COSMIC v81 release (May 2017). Genes that were recurrently mutated (three or more different cases) but not included in COSMIC were further searched in cBioPortal for Cancer Genomics (see URLs) 79 . A gene was considered a putative candidate oncogenic driver if previously reported in published literature or in the cancer gene census (COSMIC v81); if previously unreported but mutated in this study in three or more different cases (when considering the whole cohort, independently of age); and/or implicated in functional classes relevant for tumorigenesis (epigenetic regulation, cohesin, transcriptional regulation, tumor suppression, signaling pathways, splicing/RNA processing and DNA repair). The list of putative candidate driver genes was thereafter filtered for statistically significant alterations (P value < 0.05) by GRIN. Functional annotation classes were defined based on literature and The Gene Ontology Annotation (GOA) resource (see URLs) 80 . Epigenomic classes were defined according to Huether et al. 81 Co-occurrence matrix. For pairwise gene association analysis, we included genes with alterations (mutations, fusion, focal and/or relevant copy number gain and loss) in at least three AEL cases. The association between genes was tested by Fisher's exact test. The final plot was prepared using ggplot2-2.2.1 package under R-3.3.2.
Structural modeling. The residue positions for each of the three point mutants of TrkA (H498R, G617D and H766R) were identified in the apo crystal structure of the TrkA kinase domain (Protein Data Bank (PDB) ID 4F0I, ref.
43
). A cartoon representation (Fig. 5b) in a view analogous to that provided in ref. 44 was generated with the program PyMOL 82 and showed that the three mutation positions are structurally distant from each other and also removed from canonically functional features. The residue positions were numbered according to the TrkA-I isoform of this study, which differs by five residues compared to the TrkA-II isoform used in numbering the structure in PDB 4F0I. In the numbering of PDB 4F0I, the H498, G617 and H766 residues are numbered as H503, G622 and H771, respectively. The TrkA-I and TrkA-II isoforms are fully identical within the kinase domain, but differ ahead of the kinase domain by a five-residue insertion.
Retroviral cloning. Gene fusions. NUP98-KDM5A, NPM1-MLF1, MYB-GATA1, ASNS-PTPN1, PFN1-SHIP, RUNX2-STAT3
and CDC37-IL27RA fusion transcripts were amplified via reverse transcription and PCR using Phusion High-Fidelity DNA Polymerase (New England Biolabs) and the primers listed in Supplementary  Table 36 from leukemic cell cDNA. Amplification products were purified using Wizard SV Gel and PCR Clean-up system (Promega) and verified via Sanger sequencing. Purified PCR products from NUP98-KDM5A, ASNS-PTPN1, NPM1-MLF1, PFN1-SCHIP and CDC37-IL27RA were cloned into pCR-Blunt II-TOPO (Life Technologies) and subcloned into the murine stem cell virus-internal ribosome entry site-green fluorescent protein (MSCV-IRES-GFP) retroviral vector. Purified PCR products from RUNX2-STAT3 and MYB-GATA1 were cloned into the gateway entry clone pDONR221 Vector (Life Technologies) and then transferred into a Gateway-compatible MSCV-IRES-GFP vector using the LR Clonase enzyme (Life Technologies). Constructs were verified via Sanger sequencing.
NTRK1 mutations.
A gateway-compatible entry clone containing the NTRK1 cDNA was obtained from Genecopoeia (NTRK1 pDONR, GC-Z5973). The NTRK1 H498R, G617D and H766R mutations were generated by site directed mutagenesis using the Quikchange II XL Kit (Agilent Technologies) and primers in Supplementary Table 36 . Mutated cDNAs were then transferred into a Gateway-compatible MSCV-IRES-GFP vector using the LR Clonase enzyme (Life Technologies). Constructs were verified by Sanger sequencing. C-terminal 6× with Biocare TBS wash buffer (TWB954M, Biocare) rinses between steps. Slides were incubated with the primary antibody, then the secondary antibody (for CD41 goat anti-rabbit, Vector Labs BA-1000, and for CD43 rabbit anti-rat, Vector Labs BA-4001) at 1:200 for 30 min, streptavidin conjugated to horse radish peroxidase (ThermoShandon, TS-125-HR, 10 minutes) and substrate containing the chromagen DAB (ThermoShandon, TA-125-HDX, 5 min). All assay steps for Ter119 were performed on the Biocare intelliPATH with Biocare TBS wash buffer rinses (TWB954M, Biocare) between steps. Slides were incubated with the primary antibody, then with the secondary antibody (rabbit anti-rat, Vector Labs BA-4001) at 1:200 for 30 min, streptavidin conjugated to horse radish peroxidase (ThermoShandon, TS-125-HR, 10 min) and substrate containing the chromagen DAB (ThermoShandon, TA-125-HDX, 5 min). Antibodies are listed in Supplementary Table 37 .
Karyotype analysis. To evaluate chromosome ploidy and karyotypic analysis of NTRK1/TP53 R172H -mutant tumors, frozen mouse leukemic cells from spleen or liver were thawed in the Cytogenetic Shared Resource Laboratory (St. Jude Children's Research Hospital) and processed via direct harvest using routine cytogenetic methods after a 5-h colcemid exposure time. The slides were allowed to air dry for optimal banding of the chromosomes with trypsin and Wright's stain. At least 20 cells were analyzed for each tumor.
Spectral karyotype analysis. For spectral karyotype (SKY) analysis, frozen murine leukemia cells were thawed in a 37 °C water bath, added to 7 mL of media and colcemid for a 5-h exposure time and directly harvested using routine cytogenetic methods. A commercially prepared SKY probe from Applied Spectral Imaging (Carlsbad, CA) was used as the probe for this analysis. Applied Spectral Imaging protocols were followed for the hybridization and detection steps. A total of 21 metaphase cells were analyzed.
In vivo treatment with larotrectinib. For in vivo drug treatment studies, after engraftment and within two weeks after transplantation, mice were randomized to receive larotrectinib (LOXO-101) (200 mg/kg) or vehicle (Labrafac) as described in ref. 39 .
Statistical analysis.
Associations between categorical values were examined using Fisher's exact test or chi-square as appropriate. These included associations between gene/pathway-level alterations and age groups or leukemia subtypes (AEL, non-erythroid AML or MDS). Data are reported as P values without correction for multiple comparisons. P values for the gene co-occurrence matrix were determined using the Fisher exact test. The odds ratio (OR) was calculated as the ratio of odds of a mutation in gene A among those with mutation in gene B to the odds of a mutation in gene A among those without a mutation in gene B. OR > 1 indicates a positive association between two genes. Conversely, OR < 1 indicates a negative association. For clinical correlation analysis, the primary outcome was overall survival, which was defined as the time from initiation of therapy to death due to any cause or was censored at the date of last follow-up. The Kaplan-Meier method was used to estimate the survival function, and overall survival distributions were compared using log-rank tests. The Cox proportional hazards model was used to identify independent risk factors for overall survival. A stepwise regression model with variables that are significantly associated with survival in univariate analysis was carried out [84] [85] [86] . In our analyses, we specified that a variable has to be significant at the 0.25 level before it can be entered into the model, and also specified that a variable in the model has to be significant at the 0.15 level for it to remain in the model.
For in vivo mouse studies, the ANOVA test was also used to determine significance in spleen weights. Kaplan-Meier analysis and the Mantel-Cox log-rank test were used for survival data of mouse models. Analyses were performed using Prism v7.0 (GraphPad), R (see URLs) 87 , and SAS (v9. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested Mycoplasma contamination
All cell lines tested negative for micoplasma contamination.
Commonly misidentified lines (See ICLAC register)
Cell lines were not included in the database of commonly misidentified cell lines.
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals
Mice included in this study included: 1) Female 8-week old wild-type C57BL/6 mice 2) Male and female 8-week old TP53 R172H knockin mice.
Wild animals
No wild animal were used in this study
Field-collected samples
No field-collected samples were used in this study
